SCOPOLIA

OTHER NAME(S):

Belladonna, Belladonna Scopola, Escopolia, Glockenbilsenkraut, Japanese Belladonna, Russian Krainer Tollkraut, Scopola, Scopolia carniolica, Scopoliae Rhizoma, Scopolie.<br/><br/>

Overview

Overview Information

Scopolia is a plant. The root and root-like stem (rhizome) are used as medicine.

Despite serious safety concerns, people use scopolia for conditions such as spasms of the digestive and urinary tracts, liver and gallbladder complaints, pain, and many others, but there is no good scientific evidence to support these uses.

How does it work?

Scopolia contains several chemicals which are similar to prescription medications, including hyoscyamine, atropine, and scopolamine. These chemicals relax muscles lining the digestive and urinary tracts.

Uses

Uses & Effectiveness?

Insufficient Evidence for

  • Anxiety.
  • Fluid retention.
  • Gallbladder problems.
  • Liver problems.
  • Pain.
  • Spasms of the digestive tract.
  • Trouble sleeping.
  • Other conditions.
More evidence is needed to rate the effectiveness of scopolia for these uses.

Side Effects

Side Effects & Safety

When taken by mouth: Scopolia is LIKELY UNSAFE when taken by mouth as a medicine. There is only a small difference between a beneficial dose and a poisonous dose, and the amount of each chemical is different in each product. Early symptoms of scopolia poisoning include reddened skin and dry mouth. Other symptoms include high body temperature, vision problems, difficulty urinating, and constipation. Taking large amounts of scopolia can cause restlessness, compulsive speech, and hallucinations, followed by breathing problems and death.

Special Precautions & Warnings:

It is LIKELY UNSAFE for anyone to use scopolia, but people with the following conditions are especially likely to experience unwanted side effects:

Pregnancy and breast-feeding: Scopolia is LIKELY UNSAFE. Don't use it if you are pregnant or breast-feeding.

Heart problems such as congestive heart failure (CHF) or rapid, irregular heartbeat: Scopolia might make heart problems worse. Don't use it if you have one of these conditions.

Down syndrome: People with Down syndrome might be especially sensitive to the harmful effects of scopolia. Don't give it to them.

Hiatal hernia or heartburn (esophageal reflux disease): Scopolia might make esophageal reflux disease worse. Don't use it if you have this condition.

Fever: Scopolia might raise the body temperature. Don't use it if you have a fever.

Digestive tract conditions including constipation, stomach ulcers, stomach or intestinal infections, ulcerative colitis, enlarged colon (toxic megacolon), or blockage of the digestive tract: Scopolia might make digestive tract problems worse. Don't use it if you have one of these conditions.

Narrow-angle glaucoma: Scopolia might make narrow-angle glaucoma worse. Don't use it if you have this condition.

Trouble urinating (urinary retention): Scopolia might make urinary retention worse. Don't use it if you have this condition.

Interactions

Interactions?

Major Interaction

Do not take this combination

!
  • Drying medications (Anticholinergic drugs) interacts with SCOPOLIA

    Scopolia contains chemicals that cause a drying effect. It also affects the brain and heart. Drying medications called anticholinergic drugs can also cause these effects. Taking scopolia and drying medications together might cause side effects including dry skin, dizziness, low blood pressure, fast heartbeat, and other serious side effects.<br/><br/> Some of these drying medications include atropine, scopolamine, and some medications used for allergies (antihistamines), and for depression (antidepressants).

  • Medications used for depression (Tricyclic antidepressants) interacts with SCOPOLIA

    Scopolia contains chemicals that can affect the body. Some of these chemicals have effects similar to some medications used for depression. Taking scopolia might increase the side effects of some medications used for depression.<br/><br/> Some of these medicines used for depression include amitriptyline (Elavil), imipramine (Tofranil), and others.

  • Quinidine interacts with SCOPOLIA

    Scopolia can affect the heart. Quinidine can also affect the heart. Taking quinidine along with scopolia might cause serious heart problems.

Dosing

Dosing

The appropriate dose of scopolia depends on several factors such as the user's age, health, and several other conditions. At this time there is not enough scientific information to determine an appropriate range of doses for scopolia. Keep in mind that natural products are not always necessarily safe and dosages can be important. Be sure to follow relevant directions on product labels and consult your pharmacist or physician or other healthcare professional before using.

View References

REFERENCES:

  • Stewart JJ, Wood MJ, Wood CD, Mims ME. Effects of ginger on motion sickness susceptibility and gastric function. Pharmacology 1991;42:111-20. View abstract.
  • Lean ME, Noroozi M, Kelly I. Dietary flavonols protect diabetic human lymphocytes against oxidative damage to DNA. Diabetes 1999;48:176-81. View abstract.
  • Jie KG, Bots ML, Vermeer C, et al. Vitamin K status and bone mass in women with and without aortic atherosclerosis: a population-based study. Calcif Tissue Int 1996;59:352-6. View abstract.
  • Richardson, C. T. and Feldman, M. Effects of transdermal scopolamine, alone or in combination with cimetidine, on total 24 hour gastric acid secretion in patients with duodenal ulcer. Gut 1986;27(12):1493-1497. View abstract.
  • Ripamonti, C., Mercadante, S., Groff, L., Zecca, E., De Conno, F., and Casuccio, A. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial. J Pain Symptom.Manage 2000;19(1):23-34. View abstract.
  • Ritchie, J. A. and Truelove, S. C. Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. Br Med J 2-10-1979;1(6160):376-378. View abstract.
  • Rogawski M. Transdermal scopolamine and sialorrhea. Arch.Neurol. 1984;41(1):15. View abstract.
  • Samuels, L. A., Christie, L., Roberts-Gittens, B., Fletcher, H., and Frederick, J. The effect of hyoscine butylbromide on the first stage of labour in term pregnancies. BJOG. 2007;114(12):1542-1546. View abstract.
  • Schmitt, L. G. and Shaw, J. E. Alleviation of induced vertigo. Therapy with transdermal scopolamine and oral meclizine. Arch Otolaryngol.Head Neck Surg 1986;112(1):88-91. View abstract.
  • Schneider, M. and Palas, T. A. [Morphine and scopolamine in premedication. A comparison of peroral and transdermal administration with intramuscular injections]. Anaesthesist 1986;35(3):193-196. View abstract.
  • Semple P, Madej T, Wheatley R, and et al. Transdermal hyoscine with patient-controlled analgesia. Anaesthesia 1992;47(5):399-401. View abstract.
  • Shupak A, Gordon C, Spitzer O, and et al. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects. Pharmatherapeutica 1989;5(6):365-370. View abstract.
  • Sieg, H. [Double blind test using hyoscine-N-butyl bromide (Buscopan) to reduce pain in ulcus ventriculi]. Z Gastroenterol 1974;12(4):235-238. View abstract.
  • Meyer, B. R., O'Mara, V., and Reidenberg, M. M. A controlled clinical trial of the addition of transdermal scopolamine to a standard metoclopramide and dexamethasone antiemetic regimen. J Clin Oncol 1987;5(12):1994-1997. View abstract.
  • Miyoshi A. A multi-centre, double-blind evaluation against placebo of the therapeutic effect of hyosine-N-butylbromide in patients with abdominal pain. Pharmatherapeutica 1976;1(1):46-51.
  • Mora Durban MJ, Extramiana Cameno J, Arrizabalaga Moreno M, and et al. [Flubiprofen vs dipyrone combined with hyoscine: the analgesic efficacy in renal colic] (spanish). Arch Esp Urol 1995;48(9):867-873.
  • Moscovici R, Prego G, Schwartz M, and et al. Epidural scopolamine administration in preventing nausea after epidural morphine. J Clin Anesth. 1995;7(6):474-476. View abstract.
  • Mukerji V, Alpert M, Sanfelippo J, and et al. Treatment of chronic symptomatic supraventricular bradyarrhythmias with transdermal scopolamine. Chest 1988;94(1):204-205. View abstract.
  • Muskat Y, Bukovsky I, Schneider D, and et al. The use of scopolamine in the treatment of detrusor instability. J Urol. 1996;156(6):1989-1990. View abstract.
  • Nachum, Z., Shupak, A., and Gordon, C. R. Transdermal scopolamine for prevention of motion sickness : clinical pharmacokinetics and therapeutic applications. Clin.Pharmacokinet. 2006;45(6):543-566. View abstract.
  • Nieto J, Abizanda J, Pico F, Valenzuela G, and et al. Transdermal scopolamine as treatment of bradyarrhythmias. Chest 1992;101(6):1588-1590. View abstract.
  • No authors. Putting a patch on postop nausea. Nursing 2007;37(1):0.
  • Noy S, Shapira S, Zilbiger A, and et al. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea. Aviat.Space Environ.Med 1984;55(11):1051-1054. View abstract.
  • Offenloch, K., Zahner, G., Dietlein, G., and Franz, I. [Comparative in-flight study of a scopolamine-containing membrane plaster versus dimenhydrinate under defined acceleration conditions]. Arzneimittelforschung. 1986;36(9):1401-1406. View abstract.
  • Ohkawa, T., Morimoto, S., Okuyama, A., Yoshioka, T., Kishimoto, T., Kurita, T., Ikoma, F., Itatani, H., Koide, T., and Ogawa, N. [Clinical phase III study of cimetropium bromide (DA3177) on the pain with upper urinary calculus: a double-blind study in comparison with scopolamine butylbromide. DA3177 Study Group]. Hinyokika Kiyo 1997;43(7):525-538. View abstract.
  • Palm L and Blennow G. Transdermal anticholinergic treatment of reflex anoxic seizures. Acta Paediatr.Scand. 1985;74(5):803-804. View abstract.
  • PASSMORE, G. G. and SANTA CRUZ, E. W. The use of intravenous and intramuscular injections of demerol and scopolamine in labor and delivery. Am.J Obstet.Gynecol 1954;68(4):998-1008. View abstract.
  • Pedersen JE. Scopolamine as sole pre-anaesthetic medication. Acta Anaesth Scandinav 1963;7:121-129.
  • Pedretti R, Colombo E, and Braga S. Influence of transdermal scopolamine on cardiac sympathovagal interaction after acute myocardial infarction. Am.J Cardiol. 8-15-1993;72(5):384-392. View abstract.
  • Pingree, B. J. and Pethybridge, R. J. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of seasickness. Aviat.Space Environ Med 1994;65(7):597-605. View abstract.
  • Poynard, T., Regimbeau, C., and Benhamou, Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment.Pharmacol Ther 2001;15(3):355-361. View abstract.
  • Price N, Schmitt L, McGuire J, and et al. Transdermal scopolamine in the prevention of motion sickness at sea. Clin.Pharmacol.Ther. 1981;29(3):414-419. View abstract.
  • Price N, Schmitt LG, and Shaw JE. Transdermal delivery of scopolamine for prevention of motion-induced nausea in rough seas. Clin Ther 1979;2:258-262.
  • Pyykko, I., Padoan, S., Schalen, L., Lyttkens, L., Magnusson, M., and Henriksson, N. G. The effects of TTS-scopolamine, dimenhydrinate, lidocaine, and tocainide on motion sickness, vertigo, and nystagmus. Aviat.Space Environ Med 1985;56(8):777-782. View abstract.
  • Pyykko, I., Schalen, L., and Matsuoka, I. Transdermally administered scopolamine vs. dimenhydrinate. II. Effect on different types of nystagmus. Acta Otolaryngol. 1985;99(5-6):597-604. View abstract.
  • Raeder, J. C., van der, Linden J., and Breivik, H. Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine. Acta Anaesthesiol.Scand 1986;30(7):502-506. View abstract.
  • Rahko, T. and Karma, P. Transdermal scopolamine for peripheral vertigo (a double-blind study). J Laryngol Otol 1985;99(7):653-656. View abstract.
  • Recto CP, Co TV, and Clemente V. The effect of hyoscine-n-butylbromide on the first stage of labor: a clinical trial [abstract]. Acta Obstetricia et Gynecologica Scandinavica Supplement 1997;76(167):45.
  • Reinhart D, Klein K, and Schroff E. Transdermal scopolamine for the reduction of postoperative nausea in outpatient ear surgery: a double-blind, randomized study. Anesth.Analg. 1994;79(2):281-284. View abstract.
  • Eberhart, L. H., Holzrichter, P., and Roscher, R. [Transdermal scopolamine for prevention of postoperative nausea and vomiting. No clinically relevant result in spite of reduced postoperative vomiting in general surgical and gynecologic patients]. Anaesthesist 1996;45(3):259-267. View abstract.
  • Einarsson, J. I., Audbergsson, B. O., and Thorsteinsson, A. Scopolamine for prevention of postoperative nausea in gynecologic laparoscopy, a randomized trial. J Minim.Invasive.Gynecol. 2008;15(1):26-31. View abstract.
  • Estrada, A., Leduc, P. A., Curry, I. P., Phelps, S. E., and Fuller, D. R. Airsickness prevention in helicopter passengers. Aviat.Space Environ.Med 2007;78(4):408-413. View abstract.
  • Ferris, F. D., Kerr, I. G., Sone, M., and Marcuzzi, M. Transdermal scopolamine use in the control of narcotic-induced nausea. J Pain Symptom.Manage 1991;6(6):389-393. View abstract.
  • Furey, M. L. and Drevets, W. C. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch.Gen.Psychiatry 2006;63(10):1121-1129. View abstract.
  • Galeone M, Cacioli, D, Megevand J, and et al. Selection of the first-line treatment of irritable bowel syndrome - a prospective, randomised evaluation of fenoverine and hyoscine butyl bromide. European Journal of Clinical Research 1992;3:157-170.
  • Gibbons PA, Nicolson SC, Betts EK, and et al. Scopolamine does not prevent post-operative emesis after pediatric eye surgery. Anesthesiology 1984;61(3A):A435.
  • Gillin J, Sutton, L., Ruiz C, and et al. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. Biol.Psychiatry 7-15-1991;30(2):157-169. View abstract.
  • Gleiter, C. H., Antonin, K. H., Brodrick, T., Bieck, P. R., and Breucha, G. Transdermal scopolamine and basal acid secretion. N Engl J Med 11-22-1984;311(21):1378. View abstract.
  • Golding, J. F. and Stott, J. R. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate. Br.J Clin.Pharmacol. 1997;43(6):633-637. View abstract.
  • Goulston K. Diagnosis and treatment of the irritable bowel syndrome. Drugs 1973;6(3):237-243. View abstract.
  • Graybiel A, Cramer D, and Wood C. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration. Aviat.Space Environ.Med. 1982;53(8):770-772. View abstract.
  • Graybiel, A., Cramer, D. B., and Wood, C. D. Experimental motion sickness: efficacy of transdermal scopolamine plus ephedrine. Aviat.Space Environ.Med 1981;52(6):337-339. View abstract.
  • Graybiel, A., Knepton, J., and Shaw, J. Prevention of experimental motion sickness by scopolamine absorbed through the skin. Aviat.Space Environ Med 1976;47(10):1096-1100. View abstract.
  • Greenstein A, Chen J, and Matzkin H. Transdermal scopolamine in prevention of post open prostatectomy bladder contractions. Urology 1992;39(3):215-218. View abstract.
  • Guldbrand P and Mellstrom A. Rectal versus intramuscular morphine-scopolamine as premedication in children. Acta Anaesthesiol.Scand 1995;39(2):224-227. View abstract.
  • Habib, A., Sharpe, P., Anderson, S., Francis, S., Davidson, A. C., and Smith, G. Buscopan for the treatment of pain after laparoscopic sterilisation. Anaesthesia 2001;56(2):174-176. View abstract.
  • Harnett, M. J., O'Rourke, N., Walsh, M., Carabuena, J. M., and Segal, S. Transdermal scopolamine for prevention of intrathecal morphine-induced nausea and vomiting after cesarean delivery. Anesth.Analg. 2007;105(3):764-769. View abstract.
  • Harris, S. N., Sevarino, F. B., Sinatra, R. S., Preble, L., O'Connor, T. Z., and Silverman, D. G. Nausea prophylaxis using transdermal scopolamine in the setting of patient-controlled analgesia. Obstet Gynecol 1991;78(4):673-677. View abstract.
  • Homick, J. L., Kohl, R. L., Reschke, M. F., Degioanni, J., and Cintron-Trevino, N. M. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy. Aviat.Space Environ Med 1983;54(11):994-1000. View abstract.
  • Honkavaara P and Pyykko I. Effects of atropine and scopolamine on bradycardia and emetic symptoms in otoplasty. Laryngoscope 1999;109(1):108-112. View abstract.
  • Honkavaara P, Saarnivaara L, and Klemola U. Prevention of nausea and vomiting with transdermal hyoscine in adults after middle ear surgery during general anaesthesia. Br.J Anaesth. 1994;73(6):763-766. View abstract.
  • Honkavaara P. Effect of transdermal hyoscine on nausea and vomiting during and after middle ear surgery under local anaesthesia. Br J Anaesth. 1996;76(1):49-53. View abstract.
  • Horimoto Y, Tomie H, Hanzawa K, and et al. Scopolamine patch reduces postoperative emesis in paediatric patients following strabismus surgery. Can.J Anaesth. 1991;38(4 Pt 1):441-444. View abstract.
  • Howland, J., Rohsenow, D. J., Minsky, S., Snoberg, J., Tagerud, S., Hunt, S. K., Almeida, A., Greece, J., and Allensworth-Davies, D. The effects of transdermal scopolamine on simulated ship navigation and attention/reaction time. Int J Occup.Environ.Health 2008;14(4):250-256. View abstract.
  • Jackson SH, Schmitt L, McGuire J, and et al. Transdermal scopolamine as a preanesthetic drug and postoperative antinauseant and antimetic [abstract]. Anesthesiology 1982;57(3):A330.
  • Jespersen, T. W., Koch, J., Anker-Moller, E., Spangsberg, N. L., Johansen, U. T., and Grydehoj, P. [Transdermal scopolamine to prevent postoperative nausea and vomiting after uterine curettage and termination of pregnancy. A double-blind clinically controlled study with placebo]. Ugeskr Laeger 5-15-1989;151(20):1246-1248. View abstract.
  • Jones, S., Strobl, R., Crosby, D., Burkard, J. F., Maye, J., and Pellegrini, J. E. The effect of transdermal scopolamine on the incidence and severity of postoperative nausea and vomiting in a group of high-risk patients given prophylactic intravenous ondansetron. AANA.J 2006;74(2):127-132. View abstract.
  • Khadra I, Scott GC, and Braun SR. Transdermal scopolamine attenuates airways reactivity in asymptomatic asthmatics [abstract]. Am Rev Resp Dis 1988;137:329.
  • Klocker, N., Hanschke, W., Toussaint, S., and Verse, T. Scopolamine nasal spray in motion sickness: a randomised, controlled, and crossover study for the comparison of two scopolamine nasal sprays with oral dimenhydrinate and placebo. Eur.J Pharm Sci 2001;13(2):227-232. View abstract.
  • Kohl R, Sandoz G, Reschke M, and et al. Facilitation of adaptation and acute tolerance to stressful sensory input by doxepin and scopolamine plus amphetamine. J Clin Pharmacol 1993;33(11):1092-1103. View abstract.
  • Kompanje, E. J. O. 'Death rattle' after withdrawal of mechanical ventilation: practical and ethical considerations. Intensive & Critical Care Nursing 2006;22(4):214-219.
  • Koski E, Mattila M, Knapik D, and et al. Double blind comparison of transdermal hyoscine and placebo for the prevention of postoperative nausea. Br.J.Anaesth. 1990;64(1):16-20. View abstract.
  • Kotelko D, Rottman R, Wright W, and et al. Transdermal scopolamine decreases nausea and vomiting following cesarean section in patients receiving epidural morphine. Anesthesiology 1989;71(5):675-678. View abstract.
  • Kramer U and Harel S. Transdermal scopolamine for refractory seizures. J Child Neurol. 1997;12(2):139-141. View abstract.
  • Kventsel, I., Berkovitch, M., Reiss, A., Bulkowstein, M., and Kozer, E. Scopolamine treatment for severe extra-pyramidal signs following organophosphate (chlorpyrifos) ingestion. Clin.Toxicol.(Phila) 2005;43(7):877-879. View abstract.
  • La Rovere M, Mortara A, Pantaleo P, and et al. Scopolamine improves autonomic balance in advanced congestive heart failure. Circulation 1994;90(2):838-843. View abstract.
  • Laitinen, L. A., Tokola, O., Gothoni, G., and Vapaatalo, H. Scopolamine alone or combined with ephedrine in seasickness: a double- blind, placebo-controlled study. Aviat Space Environ Med 1981;52(1):6-10. View abstract.
  • Lee T, Su S, Chen M, and et al. Usefulness of transdermal scopolamine for vasovagal syncope. Am.J Cardiol. 8-15-1996;78(4):480-482. View abstract.
  • Lewis D, Fontana C, Mehallick L, and et al. Transdermal scopolamine for reduction of drooling in developmentally delayed children. Dev.Med Child Neurol. 1994;36(6):484-486. View abstract.
  • Lloret J, Muñoz J, Monmany J, and et al. Treatment of renal colic with dipyrone. A double-blind comparison trial with hyoscine alone or combined with dipyrone. Curr Ther Res 1987;42(6):1119-1128.
  • Longo D, Howser D, Wesley M, and et al. Randomized double-blind crossover trial of scopolamine vs. placebo administered by transcutaneous patch for the control of chemotherapy-induced emesis [abstract]. Proc Am Assoc Cancer Res 1981;22:161.
  • Longo, D. L., Wesley, M., Howser, D., Hubbard, S. M., Anderson, T., and Young, R. C. Results of a randomized double-blind crossover trial of scopolamine versus placebo administered by transdermal patch for the control of cisplatin-induced emesis. Cancer Treat.Rep 1982;66(11):1975-1976. View abstract.
  • Loper, K. A., Ready, L. B., and Dorman, B. H. Prophylactic transdermal scopolamine patches reduce nausea in postoperative patients receiving epidural morphine. Anesth.Analg. 1989;68(2):144-146. View abstract.
  • Markkanen, Y. J. and Pihlajamaki, K. Oral scopolamine hydrobromide solution as an antisialagogic agent in dentistry. Oral Surg Oral Med Oral Pathol 1987;63(4):417-420. View abstract.
  • McCauley M, Royal J, Shaw J, and et al. Effect of transdermally administered scopolamine in preventing motion sickness. Aviat.Space Environ.Med. 1979;50(11):1108-1111. View abstract.
  • Meijer, J. W., van Kuijk, A. A., Geurts, A. C., Schelhaas, H. J., and Zwarts, M. J. Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis. Am.J Phys.Med Rehabil. 2008;87(4):321-324. View abstract.
  • Mercadante, S., Ripamonti, C., Casuccio, A., Zecca, E., and Groff, L. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction. Support.Care Cancer 2000;8(3):188-191. View abstract.
  • Messer SN. Homeopathic treatment of pediatric otitis media. J Am-Inst Homepathy 1987;80:15-21.
  • Meyer BR, Lewin M, Pasmantier M, and et al. Clinical trial of diazepam or scopolamine with metoclopramide to ameliorate cis-platinum induced emesis [abstract]. Clin Pharmacol Ther 1983;33 :222.
  • Bosman IJ. Chapter 9. Effects of transdermal scopolamine on bronchial hyperresponsiveness to methacholine. Transdermal Delivery of Anticholinergic Bronchodilators. Methodological and Clinical Aspects. Groningen: Rijksuniversiteit Groningen;1996.
  • Bradford, T. H., Robertson, K., Norman, P. F., and Meeks, G. R. Reduction of pain and nausea after laparoscopic sterilization with bupivacaine, metoclopramide, scopolamine, ketorolac, and gastric suctioning. Obstet Gynecol 1995;85(5 Pt 1):687-691. View abstract.
  • Brand, J. J. and Whittingham, P. Intramuscular hyoscine in control of motion sickness. Lancet 8-1-1970;2(7666):232-234. View abstract.
  • Brand, J. J., Colquhoun, W. P., Gould, A. H., and Perry, W. L. (--)-Hyoscine and cyclizine as motion sickness remedies. Br.J Pharmacol. 1967;30(3):463-469. View abstract.
  • Brodtkorb E, Wyzocka-Bakowska M, Lillevold P, and . Transdermal scopolamine in drooling. J Ment.Defic.Res 1988;32 ( Pt 3):233-237. View abstract.
  • Buchhalter, A. R., Fant, R. V., and Henningfield, J. E. Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 2008;68(8):1067-1088. View abstract.
  • Casadei B, Conway J, Forfar C, and et al. Effect of low doses of scopolamine on RR interval variability, baroreflex sensitivity, and exercise performance in patients with chronic heart failure. Heart 1996;75(3):274-280. View abstract.
  • Casadei B, Conway J, Meyer TE, and et al. Effect of vagal stimulation by transdermal scopolamine on exercise performance and R-R interval variability (RRV) in patients with chronic heart failure (CHF) [abstract]. Circulation 1992;86 (Suppl 1):I-395.
  • Casadei B, Pipilis A, Conway J, and et al. Effects of vagal stimulation by transdermal scopolamine in patients post myocardial infarction [abstract]. Circulation 1991;84 (Suppl 2):II-555.
  • Casadei B, Pipilis A, Sessa F, and et al. Low doses of scopolamine increase cardiac vagal tone in the acute phase of myocardial infarction. Circulation 1993;88(2):353-357. View abstract.
  • Casadei B, Pipilis A, Sessa F, and et al. Transdermal scopolamine: a potential tool in preventing sudden death in myocardial infarction [abstract]. Eur Heart J 1991;12 (Suppl):366.
  • Chung-Hua H. [Successful use of scopolamine in acute myocardial infarction associated with resistant ventricular tachycardia]. Chin J Cardiol 1986;14(5):282-283.
  • Ciccaglione, A. F., Grossi, L., Cappello, G., Malatesta, M. G., Ferri, A., Toracchio, S., and Marzio, L. Effect of hyoscine N-butylbromide on gastroesophageal reflux in normal subjects and patients with gastroesophageal reflux disease. Am J Gastroenterol 2001;96(8):2306-2311. View abstract.
  • Clarke RS, Dundee JW, and Moore J. Studies of drugs given before anaesthesia. VI. Atropine and hyoscine. Br J Anaesth 1964;36:648-654.
  • Clarke, R. S., Dundee, J. W., and Love, W. J. Studies of drugs given before anaesthesia. 8. Morphine 10 mg alone and with atropine or hyoscine. Br J Anaesth 1965;37(10):772-778. View abstract.
  • Conner, J. T., Bellville, J. W., Wender, R., Schehl, D., Dorey, F., and Katz, R. L. Morphine, scopolamine, and atropine as intravenous surgical premedicants. Anesth.Analg. 1977;56(5):606-614. View abstract.
  • Cornella J, Bent A, Ostergard D, and et al. Prospective study utilizing transdermal scopolamine in detrusor instability. Urology 1990;35(1):96-97. View abstract.
  • Cronin, C. M., Sallan, S. E., and Wolfe, L. Transdermal scopolamine in motion sickness. Pharmacotherapy 1982;2(1):29-31. View abstract.
  • Dahl E, Offer-Ohlsen D, Lillevold P, and et al. Transdermal scopolamine, oral meclizine, and placebo in motion sickness. Clin Pharmacol Ther 1984;36(1):116-120. View abstract.
  • De Ferrari G, Mantica M, Vanoli E, et al, and . Scopolamine increases vagal tone and vagal reflexes in patients after myocardial infarction. J Am.Coll.Cardiol. 11-1-1993;22(5):1327-1334. View abstract.
  • De Ferrari GM, Mantica M, Curcuruto P, and et al. Transdermal scopolamine modifies autonomic balance after myocardial infarction [abstract]. Circulation 1991;84(4):II-266.
  • Degioanni JJ, Calkins DS, and Reschke MF. Evaluation of the efficacy of buccal scopolamine tablets (1.0 mg) in the treatment of acute motion sickness [abstract]. Aviat Space Environ Med 1990;61:484.
  • Demeter, S. L. and Cordasco, E. M. Transdermal scopolamine in the treatment of asthma: a preliminary report. J Asthma 1986;23(4):203-206. View abstract.
  • Douma WR, Bosman IJ, Rutgers SR, and et al. Effects of transdermal scopolamine on pulmonary function, symptoms and bronchial hyperresponsiveness to methacholine. Eur J Pharm Sci 1998;5(6):327-334.
  • Doyle, E., Byers, G., McNicol, L. R., and Morton, N. S. Prevention of postoperative nausea and vomiting with transdermal hyoscine in children using patient-controlled analgesia. Br J Anaesth. 1994;72(1):72-76. View abstract.
  • Dreyfuss P, Vogel D, and Walsh N. The use of transdermal scopolamine to control drooling. A case report. Am J Phys.Med Rehabil. 1991;70(4):220-222. View abstract.
  • Dukoff R, Friz J, Lasser, and et al. A comparison of effects of tacrine with scopolamine versus tacrine with placebo in patients with Alzheimer's disease [abstract]. 11th Annual Meeting of the American Association for Geriatric Psychiatry 1998;
  • Bosman IJ. Chapter 8. Effects of transdermal scopolamine on pulmonary function and symptoms in patients with (partially) reversible airways obstruction. Transdermal Delivery of Anticholinergic Bronchodilators. Methodological and Clinical Aspects. Groningen: Rijksuniversiteit Groningen;1996.
  • Abernethy, A. P., Nixon, A., Fine, P. G., Peppin, J. F., Crossno, R. J., and Bull, J. Palliative care pharmacotherapy literature summaries and analyses. J Pain Palliat.Care Pharmacother. 2007;21(3):91-97. View abstract.
  • Adigun, A. O. and Ajayi, A. A. Muscarinic blockade with oral hyoscine palliates angiotensin converting enzyme inhibitor induced cough. Afr.J Med Med Sci 1998;27(1-2):139. View abstract.
  • Al-Waili, N. and Saloom, K. Y. The analgesic effect of intravenous tenoxicam in symptomatic treatment of biliary colic: a comparison with hyoscine N-butylbromide. Eur J Med Res 10-14-1998;3(10):475-479. View abstract.
  • Anonymous. Transdermal scopolamine for motion sickness. Medical Letter on Drugs and Therapeutics 10-16-1981;23(21):89-90. View abstract.
  • Antrobus, J. H., Abbott, P., Carr, C. M., and Chatrath, R. R. Midazolam-droperidol premedication for cardiac surgery. A comparison with papaveretum and hyoscine. Anaesthesia 1991;46(5):407-409. View abstract.
  • Aronson, J. K. and Sear, J. W. Transdermal hyoscine (scopolamine) and postoperative vomiting. Anaesthesia 1986;41(1):1-3. View abstract.
  • Attias J, Gordon C, Ribak J, and et al. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea. Aviat.Space Environ.Med 1987;58(1):60-62. View abstract.
  • Babin R, Balkany T, and Fee W. Transdermal scopolamine in the treatment of acute vertigo. Ann.Otol.Rhinol.Laryngol. 1984;93(1 Pt 1):25-27. View abstract.
  • Bailey, P. L., Streisand, J. B., Pace, N. L., Bubbers, S. J., East, K. A., Mulder, S., and Stanley, T. H. Transdermal scopolamine reduces nausea and vomiting after outpatient laparoscopy. Anesthesiology 1990;72(6):977-980. View abstract.
  • Becker, G., Goossens, H., Seemann, K., Souchon, F., and Weitz, T. [Prevention of motion sickness with a transdermal therapeutic system containing scopolamine. A randomized, comparative double-blind study in the German Federal Navy]. Dtsch Med Wochenschr 12-7-1984;109(49):1881-1885. View abstract.
  • Bennett, M. I. Death rattle: an audit of hyoscine (scopolamine) use and review of management. J Pain Symptom.Manage. 1996;12(4):229-233. View abstract.
  • Bosek V and Downs JB. Nausea and vomiting after Alfentanil anesthesia: effect of transdermal scopolamine. Anesthesiol Rev 1992;19(1):19-22.

Vitamins Survey

Have you ever purchased SCOPOLIA?

Did you or will you purchase this product in-store or online?

Where did you or where do you plan to purchase this product?

Where did you or where do you plan to purchase this product?

What factors influenced or will influence your purchase? (check all that apply)

Vitamins Survey

Where did you or where do you plan to purchase this product?

Do you buy vitamins online or instore?

What factors are most important to you? (check all that apply)

This survey is being conducted by the WebMD marketing sciences department.Read More

More Resources for SCOPOLIA

CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.

This copyrighted material is provided by Natural Medicines Comprehensive Database Consumer Version. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
© Therapeutic Research Faculty 2018.